Detecting Drug Interactions From Adverse-Event Reports: Interaction Between Paroxetine and Pravastatin Increases Blood Glucose Levels
- 25 May 2011
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 90 (1), 133-142
- https://doi.org/10.1038/clpt.2011.83
Abstract
The lipid‐lowering agent pravastatin and the antidepressant paroxetine are among the most widely prescribed drugs in the world. Unexpected interactions between them could have important public health implications. We mined the US Food and Drug Administration's (FDA's) Adverse Event Reporting System (AERS) for side‐effect profiles involving glucose homeostasis and found a surprisingly strong signal for comedication with pravastatin and paroxetine. We retrospectively evaluated changes in blood glucose in 104 patients with diabetes and 135 without diabetes who had received comedication with these two drugs, using data in electronic medical record (EMR) systems of three geographically distinct sites. We assessed the mean random blood glucose levels before and after treatment with the drugs. We found that pravastatin and paroxetine, when administered together, had a synergistic effect on blood glucose. The average increase was 19 mg/dl (1.0 mmol/l) overall, and in those with diabetes it was 48 mg/dl (2.7 mmol/l). In contrast, neither drug administered singly was associated with such changes in glucose levels. An increase in glucose levels is not a general effect of combined therapy with selective serotonin reuptake inhibitors (SSRIs) and statins. Clinical Pharmacology & Therapeutics (2011) 90 1, 133–142. doi:10.1038/clpt.2011.83Keywords
This publication has 33 references indexed in Scilit:
- Robust Replication of Genotype-Phenotype Associations across Multiple Diseases in an Electronic Medical RecordAmerican Journal of Human Genetics, 2010
- The Genetic Landscape of a CellScience, 2010
- Statin Therapy and Risk of Developing Type 2 Diabetes: A Meta-AnalysisDiabetes Care, 2009
- Elevated A1C in Adults Without a History of Diabetes in the U.S.Diabetes Care, 2009
- Expert Perspective: Reducing Cardiovascular Risk in Metabolic Syndrome and Type 2 Diabetes Mellitus Beyond Low-Density Lipoprotein Cholesterol LoweringThe American Journal of Cardiology, 2008
- Depression and Anxiety in the United States: Findings From the 2006 Behavioral Risk Factor Surveillance SystemPsychiatric Services, 2008
- Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patientsAtherosclerosis, 2008
- Search for genetic variants of the SYNTAXIN 1A (STX1A) gene: the −352 A>T variant in the STX1A promoter associates with impaired glucose metabolism in an Italian obese populationInternational Journal of Obesity, 2007
- A human phenome-interactome network of protein complexes implicated in genetic disordersNature Biotechnology, 2007
- Beneficial Effects of Pravastatin on Fasting Hyperinsulinemia in Elderly Hypertensive Hypercholesterolemic SubjectsHypertension, 1996